Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

Cancer
Non Hodgkin Lymphoma (NHL)
Follicular Lymphoma
Leukemia
Chronic Lymphocytic Leukemia

For Medical Professional
Download

Basic Details

Sponsor Hoffmann-La Roche

Phase N/A

Trial Identifier NCT03374137, ML30074

Condition Chronic Lymphocytic Leukemia, Follicular Lymphoma

Official Title Post-Marketing Surveillance of Gazyva in Treatment of Patients With Gazyva in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia Patients

Study Summary

This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.

Eligibility Criteria

Gender

All

Age

≥ 18 Years

Healthy Volunteers

Inclusion Criteria

Administered obinutuzumab under the approved indications in Korea at investigator's discretion
Previously untreated with obinutuzumab

Exclusion Criteria

Out-of locally approved indications, dosage, and administration
Pregnant women, breastfeeding women
Hepatic disease
Participate in other clinical trials

This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Results Disclaimer

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

For the latest version of this information please go to www.forpatients.roche.com

Link to Third Party Site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Request a call back

First Name

Last Name

lblFpPhoneNumber

Products

When can we call you? (Free Service) 5am to 9am PST 9am to 1pm PST 1pm to 5pm PST

Don't want to wait for a callback ? Call us now

For Visitors from United States, our Privacy Statement can be reviewed below:
https://www.gene.com/privacy-policy

For Visitors from Canada, our Privacy Statement can be reviewed below:

http://www.rochecanada.com/en/content/footer-items/privacy.html

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

Basic Details

Study Summary

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

YOU ARE ABOUT TO LEAVE THE GENENTECH CLINICAL TRIALS WEBSITE

Link to Third Party Site

Contact Genentech

Contact the hospital directly

Thank you

Request a call back

Find participating medical centers and current study status in each of them

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

For the latest version of this information please go to www.forpatients.roche.com